<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>COPD MeG-CLS-032</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h1 id="chronic-obstructive-pulmonary-disease-copd">Chronic obstructive pulmonary disease (COPD)</h1>
<h2 id="executive-summary"><em>Executive summary</em></h2>
<h2 id="introduction">Introduction</h2>
<p>COPD is a chronic lung condition characterised by air-flow limitation that is not fully reversible. It usually progresses over time – either gradually or in a step-wise fashion. It is most commonly associated with smoking, but may also be associated with cooking over wood fires, exposure to dust or a history of TB.</p>
<p>COPD is not easy to diagnose. There is no single test and the diagnosis will depend on a good history and examination. Tests are at best suggestive of COPD. It is not curable but can be treated. Adequate treatment can slow the rate of progression.</p>
<h2 id="target-users">Target users</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nurses</p>
</div></li>
</ul>
<h2 id="target-area-of-use">Target area of use </h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Outpatients department</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ward</p>
</div></li>
</ul>
<h2 id="key-areas-of-focus-new-additions-changes">Key areas of focus / New additions / Changes </h2>
<p>This guideline outlines the diagnosis and management of COPD in our setting.</p>
<h2 id="limitations">Limitations</h2>
<p>Diagnosis is difficult in the absence of access to spirometry.</p>
<h2 id="diagnosis">Diagnosis</h2>
<h3 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h3>
<p>Patients complain of shortness of breath on exertion, chronic cough, often productive of sputum, wheeze and recurrent chest infections.</p>
<p>The exact degree of exertion required to bring on symptoms will vary from patient to patient. Some patients will not experience much shortness of breath but will have limited their activity levels to avoid exertion. This leads to most patients being overweight – however, patients with very severe disease can develop cachexia.</p>
<p>Most patients will give a history of smoking or other environmental exposure. A few patients may have a history of asthma which has evolved into COPD.</p>
<p>Symptoms commonly vary in severity over the day or from week to week. They are most often worse in the mornings.</p>
<h3 id="examination-findings">Examination findings</h3>
<p>Patients may be using their accessory respiratory muscles. They may purse their lips on expiration. The lungs may be over-distended, with very reduced air entry and a long expiratory phase. There may be wheeze on auscultation.</p>
<p>Patients may have signs of right heart failure in established disease. Mild ankle oedema may be seen even in the absence of heart failure. Clubbing is not typical of COPD and suggests another diagnosis.</p>
<p>The saturations should be measured. Levels below 92% on air are abnormal.</p>
<h3 id="investigation">Investigation</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Hb – anaemia commonly coexists with COPD and treatment can reduce symptoms.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Blood glucose, renal profile and electrolytes are all useful to exclude alternative causes of shortness of breath. If the renal function is normal, but the bicarbonate is raised, this is an indication of chronic under-ventilation. This is very important to note in hypoxic patients.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Spirometry is not available here. PEFR can be measured instead, but it often underestimates the degree of airflow obstruction in COPD.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Chest X-ray is important to exclude other diagnoses. About half of patients with COPD have a normal X-ray. Features supportive of a diagnosis of COPD are: increased radiolucency of the lung, flat diaphragm, long, narrow heart shadow, bullae and evidence of right heart failure.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>ECG may show right axis deviation, incomplete right bundle branch block, low voltage across all leads, persistent S waves in the precordial leads or prominent peaked P waves in leads II, III and aVF.</p>
</div></li>
</ul>
<h2 id="differential-diagnoses">Differential diagnoses</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Bronchial Asthma</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Central airway obstruction may be caused by a malignancy or by TB lymph nodes.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Bronchiectasis is very difficult to differentiate from COPD – it is suggested by daily purulent sputum production.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Heart failure usually presents with a large heart on CXR along with signs of pulmonary oedema.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>TB usually causes consolidation or other CXR signs. However, it can co-exist with COPD and about 30% of former TB patients will later develop some degree of airflow obstruction.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Rarer lung diseases that can cause progressive shortness of breath include pulmonary fibrosis and bronchiolitis obliterans.</p>
</div></li>
</ul>
<h2 id="management">Management</h2>
<h3 id="management-in-opd">Management in OPD</h3>
<p><em>This is only for stable COPD</em></p>
<p>The management of COPD is difficult in our setting – we have access neither to the investigations we need to guide treatment nor to the best treatments.</p>
<p>The most important intervention is to encourage the patient to avoid any possible causes of COPD. Smokers should be encouraged to stop and women who cook over wood fires should try to avoid this.</p>
<p>Bronchodilators have been shown to improve symptoms and exercise capacity. Short-acting bronchodilators such as salbutamol are best administered via inhaler with a spacer. A spacer can be made from a plastic bottle. They work quickly and are particularly helpful to patients with mild intermittent symptoms. They are most effective and safest when used on an as-needed basis. Salbutamol can be prescribed orally but is more likely to cause serious side effects such as cardiac arrhythmias. As COPD is by definition not fully reversible, the benefits may not outweigh the risks.</p>
<p>If further treatment is required long-acting bronchodilators (either salmeterol or tiotropium) would be recommended next. Inhaled steroids, if prescribed, should be given with these agents.</p>
<p>In the absence of access to bronchodilators, aminophylline can be used. It is controversial, but there is some evidence of an improvement in lung function and improved exercise tolerance. It is toxic in overdose.</p>
<p>Oral steroids have no place in the management of stable COPD.</p>
<h3 id="management-on-the-ward">Management on the ward</h3>
<p><em>Patients with exacerbations of COPD are managed as inpatients on the ward.</em></p>
<p>Exacerbations are characterised by increase in cough, increased sputum production and increased shortness of breath.</p>
<p>Note that 70% of exacerbations are thought to be caused by infections (bacterial or viral). Most of the remaining cases are caused by pulmonary emboli.</p>
<p>Patients with an exacerbation should be investigated with saturations, chest X-ray (to exclude pneumonia, pneumothorax, pulmonary oedema and pleural effusion), FBC, electrolytes, renal profile and glucose. Those with hypoxia (saturations &lt; 92%) or who remain breathless after a nebuliser will need admission to hospital.</p>
<p>All patients will benefit from inhaled salbutamol during an acute exacerbation.</p>
<p>Oral steroids may help a little – give prednisolone 40 mg OD for 5 days in outpatients. Courses can be extended to 14 days for those ill enough to be admitted.</p>
<p>Patients who have 2 of these symptoms will benefit from antibiotics</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>increased shortness of breath,</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>increased sputum production,</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>increased sputum purulence.</p>
</div></li>
</ul>
<p>Those who are under age 65, without heart disease and who have less than 3 exacerbations per year can be given azithromycin, doxycycline or co-trimoxazole. Other patients should be treated with ciprofloxacin or co-amoxiclav. The antibiotics should be cycled to prevent resistance – especially in those receiving regular courses.</p>
<p>Oxygen should be used in all patients with saturations &lt; 88%. It should be given via nasal prongs at an initial rate of 2 litres per minute and increased up to a rate of 6 litres per minute if necessary. The aim is to keep the saturations between 88 and 92%. Higher levels than this are associated with hypercapnia and increased mortality.</p>
<h2 id="key-issues-for-nursing-care">Key Issues for Nursing care</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Check the O<sub>2</sub> saturation. Provide oxygen via nasal prongs if O<sub>2</sub> saturation is less than 88% but do not allow to be more than 92%.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Give salbutamol nebuliser if very short of breath.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Sit patient upright – in the acute phase they will be most comfortable sitting with their arms resting on a pillow on a table. This position provides the most support to the intercostal muscles.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Encourage mobilisation.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Give patient advice to discontinue smoking and/or avoid cooking over an open wood fire.</p>
</div></li>
</ul>
<p><strong>References</strong></p>
<p>Han, Dransfield and Martinez 2017. Chronic obstructive pulmonary disease: Disease, clinical manifestations, diagnosis, and staging. UpToDate Aug 2017.</p>
<p>Ferguson and Make 2017. Management of stable chronic obstructive pulmonary disease. UpToDate June 2017</p>
<p>Stoller 2017. Management of exacerbations of chronic obstructive pulmonary disease. UpToDate Aug 2017.</p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Name: Babatunde Awokola</th>
<th>Date: 2 July 2018</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Karen Forrest</td>
<td>Date: 25 July 2018</td>
</tr>
<tr class="even">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="odd">
<td>1.0</td>
<td>New document</td>
<td></td>
</tr>
<tr class="even">
<td>2.0</td>
<td>Transferred to new template</td>
<td>31 July 2020</td>
</tr>
<tr class="odd">
<td>2.1</td>
<td>Executive summary added</td>
<td>31 July 2020</td>
</tr>
<tr class="even">
<td>Review Comments (<em>if applicable)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
